Expensive lifesaving treatments: allocating resources and maximizing access

Area of Science:

• Public Health
• Health Economics
• Pharmaceutical Policy

Background:

• Avisar et al. proposed an outreach model to maximize patient access to expensive Hepatitis C (HPC) drugs.
• National health coverage decisions for HPC drugs are influenced by high effectiveness but limited by budget impact, often targeting specific genotypes and disease stages.

Discussion:

• The study examines the political, economic, and regulatory context of HPC drug financing and provision in Israel and other nations.
• Key considerations include resource allocation for HPC drugs, outreach to patients not yet eligible for treatment, and the role of healthcare coordinators.

Key Insights:

• While national coverage is extended for highly effective HPC drugs, eligibility criteria based on disease characteristics are common globally.
• The Avisar et al. model requires further evaluation regarding resource utilization, outreach effectiveness for non-eligible patients, and cost-benefit analysis.

Outlook:

• Further research should compare the model's effectiveness against its associated costs.
• Optimizing outreach strategies and resource allocation is crucial for equitable access to HPC treatments.
• Policy development should balance budget constraints with the imperative to treat all eligible Hepatitis C patients.